July 20, 2026

Long-Term Outcomes With SABR in Primary Renal Cell Carcinoma

As reported in The Lancet Oncology by Siva et al, long-term outcomes of an Australian-Dutch phase II study (TROG 15.03 FASTRACK II) support the safety and local disease control seen with stereotactic ...

The ASCO Post

July 01, 2026

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

Dana-Farber

July 01, 2026

Dana-Farber Research News 07.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 - 15.

Dana-Farber

June 30, 2026

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma

As reported in The Lancet Oncology by Siva et al, 5-year findings in a pooled analysis of the FASTRACK and FASTRACK II trials support evidence of maintained disease control with ultra-hypofractionated...

The ASCO Post

June 30, 2026

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma

As reported in The Lancet Oncology by Siva et al, 5-year findings in a pooled analysis of the FASTRACK and FASTRACK II trials support evidence of maintained disease control with ultra-hypofractionated...

The ASCO Post

June 30, 2026

Adjuvant Belzutifan in Combination With Pembrolizumab Receives FDA Approval in Renal Cell Carcinoma

Today, the FDA approved the hypoxia-inducible factor-2 alpha inhibitor belzutifan (Welireg) in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex...

The ASCO Post

June 30, 2026

Adjuvant Belzutifan in Combination With Pembrolizumab Receives FDA Approval in Renal Cell Carcinoma

Today, the FDA approved the hypoxia-inducible factor-2 alpha inhibitor belzutifan (Welireg) in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex...

The ASCO Post

June 17, 2026

2026 AACR Renal Cell Carcinoma Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.

Dana-Farber

June 12, 2026

Dana-Farber Research Supports FDA Approval of Pembrolizumab-Belzutifan Combination for Higher-Risk Clear Cell Kidney Cancer After Surgery

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2alpha inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

Dana-Farber

June 12, 2026

Renal Cell Carcinoma: FDA Approves Adjuvant Belzutifan With Pembrolizumab

Today, the FDA approved the hypoxia-inducible factor-2 alpha inhibitor belzutifan (Welireg) in combination with pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex...

The ASCO Post